The biological activity of p53 in IW32 erythroleukemia cells was investigated. IW32 cells had no detectable levels of p53 mRNA and protein expression. By transfecting a temperaturesensitive mutant p53 cDNA, tsp53 val135 , into the cells, we have established several clones stably expressing the mutant p53 allele. At permissive temperature, these p53 transfectants were arrested in G 1 phase and underwent apoptosis. Moreover, differentiation along the erythroid pathway was observed as evidenced by increased benzidine staining and mRNA expression of ␤-globin and the erythroid-specific ␦-aminolevulinic acid synthase (ALAS-E). Treatment of cells with protein tyrosine phosphatase inhibitor vanadate blocked the p53-induced differentiation, but not that of cell death or growth arrest. Increased protein tyrosine phosphatase activity as well as mRNA levels of PTP␤2 and PTP⑀ could be observed by wildtype p53 overexpression. These results indicate that p53 induced multiple phenotypic consequences through separate signal pathways in IW32 erythroleukemia cells, and protein tyrosine phosphatase is required for the induced differentiation. Leukemia (2000) 14, 1292-1300.
Introduction
Aberration of the p53 tumor suppressor gene is the most common genetic disorder that occurs in approximately 50% of human cancers. 1 Accumulating evidence indicates that p53 acts as a guardian of genome in cells. 2, 3 In the presence of DNA damage induced by UV, 4 ␥-irradiation, 5 and chemotherapeutic agents, 6 p53 becomes stabilized and accumulated in a biochemically active form, in part as a result from phosphorylation by its upstream kinases. 7, 8 Enhanced p53 levels could also be noted in cells treated with inhibitors shown to deplete nucleotide pools 9 or to prevent spindle formation. 10 Activated p53 is responsible for cell cycle arrest and apoptosis induction; both are related to its role in protecting cells from acquisition of genomic abnormalities. In addition to maintaining the integrity of the genome, numerous reports indicate that p53 is important in regulating cell differentiation. 11 Kastan et al 12 have demonstrated that maturation of hematopoietic cells is accompanied by a simultaneous increase in endogenous p53 protein level. Introduction of wild-type p53 into the p53 nonproducers K562 erythroleukemia cells and HL-60 promyelocytic leukemia cells enhances hemoglobin synthesis 13 and induces granulocytic differentiation, 14 respectively. Expression of wild-type p53 into the p53-null DP16-1 erythroleukemia cells results in apoptosis, meanwhile, a portion of the cells display increased hemoglobin synthesis. 15 In addition to leukemia cells, p53 has been shown to mediate the nerve growth factor (NGF)-induced PC12 cell differentiation 16 and to elicit neuroendo-and myoblasts, 19 have also been suggested. Recently, it has been shown that p53 protein is activated during myoblast differentiation and participates with MyoD in the induction of muscle creatine kinase transcription. 20 All these findings suggest that p53 is a regulator of cell differentiation. Although the observation that p53 deficient-mice develop normally 21 seems to suggest that p53 is dispensable during development, a closer analysis indicates that a fraction of the p53 −/− embryos actually exhibit developmental abnormalities. 22 Moreover, establishment of wild-type p53 over-producing transgenic mice also identified a role for p53 in normal embryogenesis. 23, 24 Recent reports indicate that growth factors can modulate the cellular responses to p53. 25 For example, apoptosis induced by p53 in murine myeloid leukemia cells and erythroleukemia cells could be prevented by the presence of IL-6 26 and erythropoietin, 15 respectively. How p53 interacts with the signal transduction pathways of growth factors remains elusive. Helps et al 27 have demonstrated that 53BP2, a protein that binds p53, associates with protein phosphatase 1 (PP1) and inhibits its activity, moreover, the binding of 53BP2 to p53 and PP1 is mutually exclusive. p53 has recently been shown to activate Wip1 phosphatase, 28 additionally, it also regulates the association of its transcriptional target cyclin G with protein phosphatase 2A. 29 These studies suggest that p53 can cross-interact with cellular signaling network through modulating the phosphorylation states of the signaling components.
Numerous observations have implicated the involvement of protein tyrosine phosphatase (PTP) in cell differentiation. In the DMSO-induced murine erythroleukemia (MEL) cell differentiation, increased mRNA expression of PTP isozymes is observed, 30 in addition, exogenous overexpression of PTP␤2 triggers MEL cell differentiation. 31 Similarly, transfection of PTP1B into K562 erythroleukemia cells induces erythroid differentiation. 32 Aoki et al 33 have demonstrated that introduction of PTP20 in PC12 cells results in accelerated neurite formation following NGF treatment. We have previously shown that PTPs seem to be a common mediator of IW32 erythroleukemia cell differentiation induced by multiple signals. 34 All together, these findings suggest that PTPs play critical roles in cell differentiation.
In the present study, we have generated stable clones of IW32 erythroleukemia cells containing a temperaturesensitive p53 mutant allele, tsp53 val135 . 35 We found that wildtype p53 arrested cell growth, induced apoptosis and promoted erythroid maturation in IW32 cells. The p53-induced differentiation is associated with elevated levels of PTP expression, and PTP inhibitors inhibit p53-induced differentiation, but not that of growth arrest or apoptosis. Thus our results suggest that p53 elicited multiple cellular consequences through independent signaling events, and PTP acti-vation is required for the p53-induced differentiation of the cells.
Materials and methods

Cell culture and benzidine staining
IW32 erythroleukemia cells were cultured in RPMI 1640 (Gibco, Bethesda, MD, USA) supplemented with 10% fetal bovine serum (FBS). 36 Cells were maintained at 5% CO 2 in a humidified chamber at 37°C. Viability of cells was assessed by the trypan blue exclusion method. For hemoglobin staining, cells were reacted with 3,3Ј-dimethyl-oxybenzidine and viewed under a microscope as described previously. 37 
Plasmids and antibodies
The pLTRCGp53 val135 used for transfection was kindly provided by Dr M Oren, Weizmann Institute of Science, Israel. DNA probes that were used included the 1.7-kb HhaI fragment of pMB9 for ␤-globin, the 1.85-kb PstI fragment of pMS20 for ALAS-E, 1.5-kb XhoI/EcoRI fragment of pSKM13(−) for actin, 1-kb BamHI/KspI fragment of pSV2-p53 for p53 and the 136-bp AvaI fragment of pSK for bax. Probe for p21 was the 581-bp PCR products containing the entire p21 ORF. Probes for PTPs were generated by PCR reactions using primers complimentary to the specific genes. Antibodies against p53 were obtained from Oncogene Science (Cambridge, MA, USA).
Establishment of p53 stable clones
Transfection of IW32 erythroleukemia cells was carried out by electroporation. A 0.5 ml suspension of cells (10 7 in RPMI medium) was mixed with pLTRCGp53 val135 and pSV2-neo plasmids in a molar ratio of 10:1 and placed in a cuvette. The cells received a single electrical pulse at 250 V delivered from a 960 F capacitor (BioRad Gene Pulse, CA, USA), after which they were immediately plated in serum-containing medium. Two days later, cells were selected with 0.5 mg/ml of G418 for 15 days. The G418 resistant cells were then plated in semi-solid methylcellulose containing 10% FBS, 0.25 mg/ml G418 in RPMI 1640, and colonies formed after 12 days were isolated. Expression of p53 in these cells was verified by Western blotting.
Western blot analysis
Cells were harvested and washed with phosphate-buffered saline (PBS), and lysed with 2-3 volumes of lysis buffer (50 mM Hepes pH 7.4, 4 mM EDTA, 2 mM EGTA, 1% Triton X-100 containing 0.05 mM PMSF, 10 g/ml each of aprotinin, leupeptin and pepstatin A) for 15 min on ice. The lysate was centrifuged at 10 000 g for 30 min at 4°C and the supernatant was subjected to SDS-PAGE. The proteins were then electrotransferred to a nitrocellulose paper. For Western blot analysis, the blot was soaked in 3% nonfat milk dissolved in TBST (10 mM Tris-HCl pH 8.0, 150 mM NaCl, containing 0.05% Tween 20) for 2 h to decrease non-specific binding, membrane was then washed with TBST and reacted for 2 h with anti-p53 antibody (pAb421). The membrane was washed Leukemia three times with TBST followed by incubation with horseradish peroxidase-conjugated goat-anti-mouse IgG. Signals were detected by reacting with ECL reagents (Amersham International, Buckinghamshire, UK), followed by exposure to Xray film.
Immunoprecipitation
Cells were cultured in serum-free RPMI 1640 for 18 h, and washed twice with methionine-free medium. The cells were then incubated in methionine-free medium for 30 min and 150 Ci/ml 35 S-methionine was added for 1.5 h. The cells were washed twice with PBS and incubated with 1 ml PBS containing 1% Triton X-100, 0.5% sodium deoxycholate, and 0.1% SDS on ice for 10 min, then passed through a 21-gauge needle and centrifuged at 30 000 g for 30 min. The supernatant was reacted with anti-p53 antibodies at 4°C for 18 h followed by protein A coupled Sepharose 4B for 2 h and the immunoprecipitates were collected by centrifuging at 500 g for 5 min.
Flow cytometry analysis
IW32-derived cells (2 × 10 6 ) were harvested and resuspended in 2 ml PBS. After fixing in 5 ml 70% ethanol at 4°C for more than 18 h, they were stained with a solution containing 0.04 mg/ml propidium iodide and 0.1 mg/ml RNase A at 37°C for 30 min. Samples were kept at 4°C in the dark and were analyzed by a fluorescence-activated cell sorter FACSort (Becton Dickinson, San Jose, CA, USA).
RNA preparation and Northern blot analysis
Total RNA was isolated by the Tri Reagent (Molecular Research Center, Cincinnati, OH, USA) according to the manufacturer's instructions. Poly(A) + RNA was isolated by mixing 500 g of total RNA to the Qiagen Oligotex mRNA spin column (Qiagen, Valencia, CA, USA), and mRNA was eluted with 5 mM Tris-HCl, pH 7.5. For Northern blot analysis, RNA was denatured with formamide/formaldehyde and applied to a 1.2% agarose gel containing formaldehyde. After electrophoresis, the RNA was transferred to a nitrocellulose paper and hybridized with 32 P-labeled DNA. The radioactivity was analyzed by a PhosphoImager (Molecular Dynamics, Sunnyvale, CA) or by exposing the membrane to a Kodak Xray film.
Measurement of PTP activity
PTP assay was measured using the synthetic substrate of p-nitrophenyl phosphate (p-Npp) according to Aoki et al. 33 Total cell extracts were prepared by lysing the cells in a buffer containing 50 mM Hepes, 150 mM NaCl, 1 mM EDTA, 10% glycerol, 1% Triton X-100, 1 mM PMSF and 10 g/ml aprotinin, pH 7.5. The reaction was started by adding 30 g of lysate protein to a solution containing 25 mM MES, pH 5.5, 1.6 mM dithiothreitol, and 10 mM p-Npp in a total volume of 200 l. The reaction was carried out at 37°C for 30 min and was stopped by the addition of 100 l of 1 N NaOH. The extent of each reaction was estimated by measurement of the absorbance at 405 nm. Vanadate-sensitive PTP activity was determined by subtracting the activity in the presence of 10 M sodium vanadate from that obtained in the absence of the drug, and okadaic acid-sensitive PTP activity was determined by subtracting the activity in the presence of 0.01 M okadaic acid.
Results
Generation of IW32 cells expressing the tsp53 val135 allele
Since many tumor cells are associated with p53 inactivation, we first examined the expression of p53 in IW32 murine erythroleukemia cells. These cells were originally cloned from spleens of mice infected with the helper component of Friend virus. 36 Total RNA was prepared from IW32 cells and analyzed by Northern blotting, RNA isolated from normal mouse spleen was included as a positive control for p53 expression. As shown in Figure 1a , IW32 cells did not express a detectable amount of p53 mRNA when compared with normal mouse Expression of p53 in IW32 erythroleukemia cells. (a) Total RNA was isolated from IW32 erythroleukemia cells and normal mouse spleen and separated by agarose gel electrophoresis. p53 mRNA expression was analyzed by Northern blotting as described in the Materials and methods. As an internal control, the same blot was hybridized with DNA of glyceraldehyde 3-phosphate dehydrogenase (GAPDH). (b) Total cell extracts were prepared from IW32 erythroleukemia cells and NIH:OVCAR-3 human ovarian carcinoma cells metabolically labeled with 35 S-methionine, and immunoprecipitated with anti-p53 antibodies (pAb421, 240 and 246) as described in the Materials and methods. The precipitates were separated by 10% SDS-PAGE, radioactivity was detected by an X-ray film.
spleen. Lack of p53 expression in these cells was also supported by the results from immuno-precipitation. IW32 cells metabolically labeled with 35 S-methionine were lysed and precipitated with epitope-specific antibodies pAb246 (reacting with wild-type p53), pAb240 (reacting with mutant p53) and pAb 421 (reacting with both wild-type and mutant p53). As seen in Figure 1b , none of the above antibodies recognized any specific proteins in IW32 cell lysates when compared to the non-immune antibodies. As a positive control, pAb421 precipitated a 53 kDa protein in lysates of NIH:OVCAR-3 human ovarian carcinoma cells known to express a point-mutated p53. These results together showed that IW32 erythroleukemia cells do not have endogenous p53 expression.
In an attempt to elucidate the biological activity of wildtype p53 in IW32 erythroleukemia cells, we transfected the tsp53 val135 cDNA together with the neomycin-resistant construct pSV2neo, into IW32 cells. pSV2neo alone was introduced into cells as a transfection control. The expression of exogenous p53 protein in the stable transfectants was evaluated by Western blotting. As indicated in Figure 2 , while the expression of p53 protein was undetectable in parental IW32 cells as well as in cells transfected with pSV2neo alone (Neo), the tsp53 val135 and pSV2neo co-transfectant clones 1-5, 2-21 and 2-22 expressed elevated levels of p53 protein. Densitometry analysis of the relative amounts of p53 in clones 1-5, 2-21 and 2-22 were 1, 0.4 and 2.5, respectively.
p53 expression is associated with multiple phenotypic consequences in IW32 cells
The biological function of p53 in IW32 cells was next examined by culturing the transfectants at permissive temperature (32.5°C). As can be seen in Figure 3a , at 32.5°C, all three tsp53 val135 clones stopped proliferation whereas Neo and parental IW32 cells continued to increase in number. Analysis by trypan blue exclusion indicated that the percentages of viable cells decreased with time of incubation at permissive temperature in all three transfectants, although to different degrees. After culturing at 32.5°C for 3 days, fractions of cells remained viable were 84%, 60% and 44%, for clones 1-5,
Figure 2
Expression of p53 protein in stable transfectants of IW32 cells. Total cell extracts were prepared from IW32-derived stable clones including cells transfected with pSV2neo alone (Neo), and those cotransfected with tsp53 val135 and pSV2neo (clones 1-5, 2-21 and 2-22). The proteins were separated by 10% SDS-PAGE, blotted on to a nitrocellulose paper, and reacted with antibodies (pAb421) against p53 and ␣-tubulin.
Figure 3
Growth and viability of IW32-derived cells at 32.5°C. Cells (clones 1-5, 2-21, 2-22 and Neo) were harvested at various times after transferring to 32.5°C, the cell number (a) and % viability as determined by trypan blue exclusion (b) were obtained. Alternatively, cells cultured at 38.5°C (left panels) or those shifted to 32.5°C for 48 h (right panels) were harvested, stained with propidium iodide as described in the Materials and methods, and analyzed by flow cytometry for cell cycle distribution (c).
2-22 and 2-21, respectively (Figure 3b ). In line with these results, flow cytometry analysis showed that after incubation at 32.5°C for 48 h, the population of cells in G 1 phase increased substantially with a concomitant decrease of cells in S phase for all three sublines (Figure 3c) . Meanwhile, the sub-G 1 fractions increased significantly for clones 2-21 (23%) and 2-22 (14%), suggesting that p53 elicited apoptosis in these cells. The cell cycle distribution of Neo cells was not affected by temperature downshifting. More detailed time course analysis on clone 1-5 indicated that the increase in G 1 population preceded the appearance of the sub-G 1 populations (data not shown), suggesting that p53 induced an early G 1 arrest. That p53 induced apoptotic death in these cells was also demonstrated by the appearance of DNA ladder characteristic of apoptosis (data not shown). These results together demonstrated that wild-type p53 induced G 1 arrest and elicited apoptosis of IW32 cells.
When cultured at 32.5°C, the tsp53 val135 sublines were shown to mature along the erythroid pathway, as indicated by increased hemoglobin expression determined by benzidine staining (Figure 4a ). After 3 days at permissive temperature, benzidine-positive cells increased to 69%, 45% and 31% for clones 1-5, 2-22 and 2-21, respectively. In these transfectants, the percentages of differentiating cells were inversely Leukemia correlated with those of the apoptotic cells. It appears that a subpopulation of cells survived the apoptotic fate and underwent erythroid differentiation. As a control, Neo and parental IW32 cells did not exhibit an appreciable extent of erythroid differentiation or cell death upon temperature downshifting. The p53-induced differentiation was further demonstrated by the expression of erythroid-specific markers. As shown in Figure 4b , mRNA expression of ␤-globin and ALAS-E, the rate-limiting enzyme in the heme synthesizing pathway, increased significantly at 32.5°C. Taken together, we have shown that wild-type p53 induced multiple phenotypic consequences, including growth arrest, apoptosis and differentiation, in IW32 erythroleukemia cells.
p53-induced differentiation, but not that of cell death or growth arrest, is dependent on PTP
As mentioned, PTPs have been shown to play important roles in the differentiation of cells, we therefore examined the possibility of their involvement in p53-mediated differentiation. The tsp53 val135 expressing sublines were treated with PTP inhibitor sodium vanadate for 30 min before transferring to 32.5°C. As indicated, vanadate dose dependently inhibited
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Figure 4
Induction of erythroleukemia cell differentiation by wildtype p53 expression. (a) IW32-derived cells were shifted from 38.5°C to 32.5°C for the indicated times. Cells were harvested and differentiation was determined by benzidine staining as described in the Materials and methods. (b) Clone 1-5 cells were shifted from 38.5°C to 32.5°C. At the indicated times, total RNA was isolated, and analyzed by Northern blotting for the expression of ␤-globin and ALAS-E. The same blot was hybridized with 32 P-labeled ␤-actin as an RNA loading control. the p53-induced differentiation (Figure 5a ). At 10 M, the differentiation was virtually abolished. Similarly, phenylarsineoxide (PAO), another potent inhibitor of PTP, also inhibited the p53-induced differentiation of clone 1-5 cells (Figure 5b) . In contrast, a serine/threonine phosphatase inhibitor okadaic acid had no effect on the p53-induced differentiation (data not shown). Consistent with benzidine staining, Northern blot analysis demonstrated that vanadate inhibited the p53-induced mRNA accumulation of ␤-globin and ALAS-E ( Figure  5c ). These tsp53 val135 stable transfectants, however, remained susceptible to the p53-induced cell death or growth arrest in the presence of vanadate. As shown by flow cytometry analysis, it was clear that the increased distribution of cells in G 1 and sub-G 1 phases of the cell cycle resulted from wild-type p53 expression was not affected by vanadate. The cell cycle distribution remained essentially indistinguishable in these cells treated with or without vanadate ( Figure 6 ). These results support the notion that p53-induced differentiation is mediated by an independent pathway, and is not merely a consequence of its ability to arrest growth.
We next examined the expression of two p53 downstream 
Figure 6
Vanadate does not inhibit the p53-induced apoptosis or growth arrest. IW32-derived clones (clones Neo, 1-5 and 2-22) were treated with (right panels) or without (left panels) vanadate (10 M) for 30 min, cells were then cultured at 32.5°C for 48 h. At the end of the incubation, cells were harvested, stained with propidium iodide as described in the Materials and methods, and analyzed by flow cytometry for cell cycle distribution.
target genes, p21 38 and Bax, 39 whose gene products were implicated in the p53-mediated growth arrest and apoptosis, respectively. As indicated by Northern blot analysis (Figure 7) , enhanced p21 mRNA expression was observed in all three sublines, consistent with the observation that wild-type p53 elicited G 1 arrest in these cells. Moreover, induction of p21
Figure 7
Effect of vanadate on the p53-induced p21 and Bax mRNA expression. The IW32-derived stable transfectants were incubated in the presence (+) or absence (−) of 10 M sodium vanadate for 30 min, cells were then cultured at 32.5°C for the indicated times. Total RNA was extracted and analyzed by Northern blotting for the expression of p21 and Bax. The same blot was hybridized with DNA of 18S RNA as an internal control.
Leukemia persisted in the presence of vanadate where cells continued to be arrested. Elevated Bax mRNA expression was also found in all three tsp53 val135 transfectants at 32.5°C. Unexpectedly, vanadate inhibited Bax mRNA expression to that of the noninduced levels, irrespective of its inability to block cell death. Thus the Bax gene expression did not seem to correlate with the apoptotic states of these cells. Control experiments showed that temperature down shifting had no effect on either p21 or Bax mRNA induction of Neo cells that do not express the tsp53 val135 allele, again indicating that induction of p21 and Bax is not a non-specific temperature effect.
Increased PTP activity and mRNA expression in wildtype p53 over-expressing cells
We next examined whether increased PTP activity could be detected in tsp53 val135 transfectants cultured at permissive temperature. Total cell extracts were prepared from clone 1-5 cells and control Neo cells after cultured at 32.5°C for 3 days, and PTP activity was measured using p-Npp as a substrate. 33 As shown in Table 1 , a significant increase in p-Npp hydrolyzing activity was observed in clone 1-5 cells after temperature shifting (P Ͻ 0.01), moreover, the majority of this increase (Ͼ70%) could be attributed to the activity of vanadate-sensitive PTPs. Control Neo cells did not exhibit any appreciable elevation in p-Npp hydrolysing activity, indicating that the increase is not a non-specific temperature effect.
To further investigate the mechanisms underlying the increases in PTP activity, we examined changes in mRNA levels of several selected PTPs including PTP␤2, PTP⑀, SH-PTP2 and Cdc25M2 that have been shown to have enhanced mRNA expression during the DMSO-induced MEL cell differentiation. 30 Differential induction of PTP␤2 and PTP⑀ transcript levels was found ( Figure 8) ; elevated mRNA expression could be detected as early as 2-6 h after temperature downshifting and persisted until 72 h, the last time point analyzed. By contrast, transcript level of Cdc25M2 decreased significantly while that of SH-PTP2 was not affected during the course of p53 induced differentiation.
Discussion
p53 tumor suppressor plays an important role in regulating cell growth, apoptosis and differentiation. By transfecting the tsp53 val135 cDNA into the p53 non-producer IW32 erythroleukemia cells, we have demonstrated that wild-type p53 arrested cells in G 1 , cells then underwent either erythroid differentiation or apoptosis. The proportion of the differentiating cells was inversely correlated to that of the apoptotic cells and vanadate inhibited only the p53 induced-differentiation without impairing its effects on cell death and growth arrest. It is clear that differentiation requires protein tyrosine phosphatase and is not merely a consequence of the ability of p53 to arrest cell proliferation. In accord with other studies, our results support the notion that the cellular responses to p53 are differentially regulated functions and may be mediated by different signal transduction pathways.
Although the involvement of p53 in normal hematopoiesis is unclear, numerous studies have linked p53 expression to the differentiation of leukemia cells. Overexpression of p53 in K562 cells 13 and DP16-1 erythroleukemia cells 15 increases hemoglobin production, in addition, p53 induces the differentiation of HL60 human promyelocytic leukemia cells. The tsp53 val135 transfectant clone 1-5 and the control Neo cells were cultured at 32.5°C for 0 and 3 days. Cells were harvested, and total cell lysates prepared. PTP activity was assayed using p-Npp as a substrate according to that described in the Materials and methods. Vanadate-sensitive PTP activity was determined by subtracting the activity in the presence of 10 M sodium vanadate from that obtained in the absence of the drug. Okadaic acid-sensitive PTP activity was determined by subtracting the activity in the presence of 0.01 M okadaic acid from that in the absence of the drug. Results are mean ± standard deviation of three independent experiments, each performed in triplicate. a P Ͻ 0.01; b P Ͻ 0.002; c P Ͼ 0.05 by Student's t-test.
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Figure 8
Effects of wild-type p53 on the mRNA expression of several selected PTPs. Clone 1-5 cells were cultured at 32.5°C for the indicated time points, poly(A) + RNA was isolated and analyzed by Northern blotting for the expression of the PTPs as described in the Materials and methods. As an internal control, the same blot was hybridized with 32 P-labeled ␤-actin cDNA.
Involvement of p53 in the growth factor-induced leukemia cell differentiation has also been demonstrated. For example, Ehinger et al 41 have shown that p53 is a mediator of the TGF-␤1 induced differentiation of K562 and U937 cells. In addition, p53 acts synergistically with interferon ␥ in inducing the differentiation of U937 leukemia cells. 42 Our results that p53 induced G 1 arrest and erythroid differentiation of IW32 cells further substantiate the proposal that it plays an important role in erythroleukemia cell differentiation and imply that p53 inactivation releases cells from G 1 cycle arrest and suppresses cell differentiation.
It has been demonstrated previously that wild-type p53 causes growth arrest of cells in some situations whereas in other instances, p53 activation induces programmed cell death. Still in others, cells are resistant to the p53-mediated growth arrest, apoptosis or differentiation. 43 The decision of whether p53 renders cells to a particular outcome may, in part, reside on the cellular context and its interplay with extracellular signals. This has been clearly demonstrated by studies indicating that the presence of RB or interleukin 3 (IL-3) can jointly modulate the choice between p53-dependent cycle arrest or apoptosis in DA-1 lymphoid cells. 25 Levels of p53 expression are another determinant of a particular cell fate. It has been shown that high levels of p53 trigger apoptosis while low levels induce differentiation of HL60 cells. 40 However, differences in the responses of IW32 sublines to p53 are not simply attributable to differences in p53 expression levels; our analysis indicated that the amounts of p53 in these sublines had no absolute correlation with their responses to p53. The 2-21 cells whose p53 level was comparable to that of 1-5, underwent mostly apoptosis, while 1-5 cells remained predominantly viably arrested and differentiated along the erythroid pathway in response to wild-type p53.
A possible explanation of why p53 elicited different fates within a clonal erythroleukemia line may reside on the fact that the responses could be cell cycle dependent. These cells were not synchronized before p53 expression, and thus may assume different cellular background at the beginning of the experiments. p53 is a phosphoprotein that is multiply phosphorylated at serines and threonines in vivo and in vitro, and phosphorylation has been shown to alter the activity of p53. As a consequence, the differences in cell cycle may influence the transcriptional activities of p53 protein that, in turn, may result in activation of differential sets of target genes. 44 Our findings that PTP is required for the p53-induced erythroleukemia cell differentiation is in line with many other recent studies linking PTPs to the differentiation of cells of various types. Although much less is known regarding the regulation of PTPs during differentiation, increased levels of PTP transcripts have been observed in many differentiating systems, suggesting that activation of PTPs often take place at the level of gene expression. For example, the DMSO-induced MEL cell differentiation is associated with increased levels of several PTP transcripts. 30 Induction of specific PTP has also been reported in the differentiation of M1 cells induced by IL-6, in HL-60 cells by PMA, 45 and during the differentiation of NGF-stimulated PC12 cells. 33 Our results that the activity of PTP increased significantly, together with enhanced mRNA expression of PTP␤2 and PTP⑀ in the wild-type p53 overexpressing transfectants, suggest that PTP activity may be modulated at the level of gene expression. The fact that induction of PTP mRNA levels was observed at an early time after wildtype p53 expression, prior to any detectable morphological or biochemical characteristics of differentiation and apoptosis, further indicates that upregulation of PTP may be a primary event of p53 signaling in erythroleukemia cells.
Substantial evidence suggests that a major part of p53-mediated growth arrest proceeds through induction of p21, a cyclin-dependent kinase inhibitor. 38 In accord with this, we found that p21 mRNA was induced in all three tsp53 val135 transfectants. Moreover, vanadate which was unable to inhibit p53-induced G 1 arrest, did not affect its induction of p21 in these sublines. These data are consistent with the suggestion that p53-elicited G 1 arrest in IW32 cells is likely due to its induction of p21 gene expression. In contrast, the decision of the arrested cells to undergo apoptosis is less clear. Among the p53 target genes, Bax 39 is an obvious candidate for mediating the p53-induced apoptosis. Enhanced Bax mRNA expression was noted in all three tsp53 val135 sublines cultured at permissive temperature that, at first sight, appears to correlate with the p53-induced apoptosis in these cells. However, in the presence of vanadate, Bax mRNA activation was inhibited to non-induced levels despite the fact that p53-induced apoptosis persisted. The lack of correlation between apoptotic state and Bax expression in these cells suggests that additional events may be required for p53 to elicit apoptosis.
In conclusion, we have shown that multiple pathways are activated by p53 in IW32 erythroleukemia cells that cause the cells to undergo growth arrest, differentiation, and cell death, and PTP activation at the level of mRNA expression may be responsible for p53-mediated erythroid differentiation.
